APHIS: Reopening Comment Period for Dog Care Standards
The Animal and Plant Health Inspection Service (APHIS) has reopened the comment period for its request for information regarding standards for the care of breeding female dogs and exercise/socialization for dogs subject to the Animal Welfare Act. The new comment deadline is April 20, 2026.
USPTO Patent Grant: Composition for Improving Muscle Function
The USPTO has granted patent US12582623B2 to N.V. Nutricia for a composition comprising EPA, MA, and leucine. This composition is intended for the prevention and/or treatment of diseases involving muscle decline or for improving muscle function.
Nestle Patent for MCTs Improving Cognitive Function
The USPTO has granted Nestle a patent (US12582627B2) for MCT formulations designed to improve cognitive functions, such as memory and executive function, and to prevent or treat mild cognitive impairment (MCI). The patent specifies daily dosages and composition ratios of medium chain triglycerides, particularly octanoic acid.
USPTO Patent Grant: Dapansutrile for Breast Cancer Treatment
The USPTO has granted patent US12582628B2 to Olatec Therapeutics, Inc. for a method of treating breast cancer using dapansutrile, optionally in combination with a checkpoint inhibitor. The patent covers methods of treatment and has an effective date of March 24, 2026.
USPTO Patent Grant for Improving Kidney Function
The USPTO has granted patent US12582631B2 to Chinook Therapeutics, Inc. for methods of improving kidney function. The patent, which includes 36 claims, was filed on August 16, 2022, and granted on March 24, 2026.
USPTO Patent Grant for CAH Treatment Compound
The USPTO has granted patent US12582634B2 to Neurocrine Biosciences, Inc. for a compound and synthetic methods for treating congenital adrenal hyperplasia (CAH). The patent covers specific chemical structures and their preparation, aiming to provide new therapeutic options for this condition.
USPTO Grants Patent for Sodium Oxybate to Treat Idiopathic Hypersomnia
The United States Patent and Trademark Office (USPTO) has granted patent US12582622B2 to Jazz Pharmaceuticals Ireland Limited for methods of treating idiopathic hypersomnia with sodium oxybate. The patent is effective March 24, 2026.
USPTO Patent Grant for Viral Infection Compounds Targeting Sigma Receptors
The USPTO has granted a patent (US12582619B2) to Thomas Jefferson University for compounds that modulate Sigma receptors to treat viral infections. The patent covers methods for preventing, treating, or ameliorating viral infections using these compounds, potentially in combination with other therapeutic agents.
USPTO Grants Patent for Benzothiazole Compound for Parkinson's and Restless Leg Syndrome
The USPTO has granted a patent (US12583829B2) to Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. for a salt of a benzothiazole compound and its crystal form. The patent covers the use of this compound in the preparation of drugs for treating Parkinson's disease and restless leg syndrome.
USPTO Patent Grant for GIP Receptor Antibodies
The USPTO has granted patent US12583930B2 to Crystal Bioscience Inc. for GIP receptor antibodies designed to treat metabolic disorders, specifically those related to glucose metabolism. The patent covers antibodies that bind to and inhibit the human glucose-dependent insulinotropic polypeptide (GIP) receptor.
USPTO Patent Grant: ARDS Treatment with G-CSF Inhibitors
The USPTO has granted patent US12583929B2 to CSL Innovation Pty Ltd for methods of treating acute respiratory distress syndrome (ARDS) using compounds that inhibit G-CSF signaling. The patent covers compounds and their use in manufacturing medicaments for ARDS prevention and treatment.
USPTO Patent for Alzheimer's Treatment Using LRP1/SorLA Antagonist
The USPTO has granted a patent (US12583920B2) to the University of Maryland, Baltimore, for methods and compositions to treat or prevent Alzheimer's disease using LRP1 and/or SorLA antagonists. The patent covers specific therapeutic approaches targeting tau internalization and trafficking in neuronal cells.
USPTO Grants Patent for Flavivirus Cross Neutralizing Antibody
The USPTO has granted patent US12583912B2 for a flavivirus cross-neutralizing antibody developed by the Japan Institute for Health Security. This antibody specifically targets the E protein of flaviviruses, including Zika, dengue, and Japanese encephalitis viruses, and aims to control infection with suppressed Antibody-Dependent Enhancement (ADE).
USPTO Patent Granted for Cognitive Disorder Treatment Compound
The USPTO has granted patent US12583884B2 to AELIS FARMA for a compound, 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one, for use in treating cognitive disorders. The patent filing date was December 18, 2019.
USPTO Patent Grant: Immunopotentiating Amino Acid Mineral Complex
The USPTO has granted a patent (US12583873B2) to BTN CO., LTD. for an amino acid mineral complex with immunopotentiating activity. This complex can be used in compositions for foods, pharmaceuticals, or feeds to enhance immunity or antibody production in humans and animals.
USPTO Patent Grant: Tumor Treatment with Antibodies
The USPTO has granted patent US12582713B2 to Bristol-Myers Squibb Company for methods of treating tumors using pharmaceutical compositions containing anti-PD-1 or anti-PD-L1 antibodies, particularly for subcutaneous delivery. The patent also covers compositions that include an endoglycosidase hydrolase enzyme.
USPTO Grants Patent for Glutathione Trisulfide in Neuroprotection
The USPTO has granted a patent (US12582693B2) to The General Hospital Corporation for methods using glutathione trisulfide (GSSSG) in neuroprotection. The patent covers uses in treating neurodegenerative diseases and reducing ischemic injury risk.
USPTO Patent Grant: Botulinum Toxin for Infertility Treatment
The USPTO has granted a patent (US12582705B2) to CHA UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a composition comprising botulinum toxin or a salt thereof. This composition is intended to increase endometrial blood flow and improve implantation potential, potentially treating subfertility or infertility.
Patent for Crohn's Disease Indicator and Treatment
The USPTO has granted Washington University a patent (US12582696B2) for methods to treat, select, and monitor inflammatory bowel disease using Debaryomyces species as a biomarker. The treatment involves administering an antifungal compound and detecting fungal DNA or antibodies.
USPTO Patent Grant: Peptides for Treating Glioma Tumors
The USPTO has granted patent US12582695B2 for peptides, compositions, and methods to treat glioma tumors infiltrated with macrophages. The patent was filed on November 27, 2019, and is assigned to Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk.
USPTO Grants Patent for Compounds Inhibiting Protozoan Parasites
The USPTO has granted a patent (US12582694B2) to the University of South Florida for compounds and methods designed to block protozoan parasite invasion and liver-stage development, specifically mentioning Plasmodium falciparum. This patent covers novel therapeutic approaches for treating parasitic infections.
USPTO Patent Grant US12582691B2: Yunnan Baiyao/Xingnaojing for TBI
The USPTO has granted patent US12582691B2 to Lotus Biotech.com LLC for methods of administering Yunnan Baiyao or Xingnaojing to patients with moderate-to-severe traumatic brain injury (TBI) and craniotomy. The patent covers methods for improving postoperative recovery and inhibiting adverse impacts associated with TBI and related neurological conditions.
USPTO Patent Grant: Cancer Treatment Compositions
The USPTO has granted a patent (US12582690B2) to the Korea Institute of Science and Technology for compositions containing Rubus longisepalus var. tozawai extracts for preventing or treating cancer. The patent details specific anticancer efficacy against various cancers, including diffuse-type gastric cancer.
USPTO Grants Patent for Terpenoids in Fibrotic Disease Treatment
The USPTO has granted patent US12582689B2 to ARJIL BIOTECH HOLDING COMPANY LIMITED for a method of treating or preventing fibrotic diseases using terpenoids extracted from Antrodia-camphorate or Anisomeles indica. The patent was granted on March 24, 2026.
USPTO Patent Grant: Bone Fracture Recovery Composition Manufacturing Method
The USPTO has granted a patent (US12582686B2) for a manufacturing method of a composition designed to promote bone fracture recovery. The method involves preparing and processing a specific mixture of herbal and natural ingredients into a liquid extract.
USPTO Patent Grant: Allergy Treatment Compositions
The USPTO has granted patent US12582679B2 to Vedanta Biosciences, Inc. for compositions and methods for treating allergy, including food allergy. The patent covers novel approaches to modulating immune responses and inducing immune tolerance or desensitization.
Immunotherapy Patent for H3K27M Mutation Cancers Issued
The USPTO has issued a new patent (US12582675B2) to The Board of Trustees of the Leland Stanford Junior University for methods of treating cancers harboring an H3K27M mutation using immunotherapy. The patent details the use of immune cells engineered to express GD2-specific chimeric antigen receptors.
Vanadium Compounds Patented for Cancer Treatment
The USPTO has granted a patent (US12582672B2) to The Broad Institute, Inc. for vanadium compositions and methods for treating cancers, particularly those expressing elevated levels of SLC26A2. The patent covers the use of bis(maltolato)oxovanadium(IV) (BMOV) and related compounds.
USPTO Patent Grant: Lignin Solvation for Antimicrobial Therapeutics
The USPTO has granted a patent (US12582670B2) to the University of Florida Research Foundation, Inc. for a method of solvating lignin in aqueous buffers for use in antimicrobial therapeutics. The patent covers aqueous lignin solutions and their applications in treating microbial infections and forming antimicrobial products.
USPTO Patent US12582667B2 for Gastrointestinal Cancer Treatment
The USPTO has granted patent US12582667B2 to The Rockefeller University for compounds and methods to treat metastatic gastrointestinal cancer. The patent details a method involving suppressing the enzymatic activity of DHODH and/or decreasing creatine levels via suppression of the creatine transporter SLC6a8.
USPTO Patent Grant for Low Dose Therapeutic Treatment
The USPTO has granted patent US12582666B2 to Syqe Medical Ltd. for a low dose therapeutic treatment system. The patent covers a system for delivering predetermined amounts of THC, with specific limits on dosage and delivery time, utilizing a decision module and an inhaler device.
USPTO Patent Grant for Injectable Pharmaceutical Compositions by Zoetis
The USPTO has granted patent US12582662B2 to Zoetis Services LLC for injectable pharmaceutical compositions. The patent covers formulations including a cyclodextrin, a hydrophobic drug, a co-solvent, and a preservative, designed for effective preservation according to pharmacopoeia standards.
USPTO Grants Patent for RSV Inhibitors
The USPTO has granted a new patent (US12582661B2) to SHANGHAI ARK BIOPHARMACEUTICAL CO., LTD. for a class of respiratory syncytial virus (RSV) inhibitors. The patent, effective March 24, 2026, covers compounds with potential advantages in activity and in vivo exposure compared to existing treatments.
USPTO Patent Grant: Methods Treating Disorders Using CSFIR Inhibitors
The USPTO has granted patent US12582655B2 to Deciphera Pharmaceuticals, LLC for methods of treating cancers and other tumors using CSFIR inhibitors. The patent covers methods related to the proliferation, depletion, or repolarization of tumor-associated macrophages (TAMs).
USPTO Grants Patent for Idiopathic Pulmonary Fibrosis Treatment
The USPTO has granted a patent (US12582653B2) to BEIJING TIDE PHARMACEUTICAL CO., LTD. for a compound and method to treat idiopathic pulmonary fibrosis. The patent covers compounds represented by formula (I) and their pharmaceutically acceptable derivatives.
USPTO Patent for Hair Follicle Regeneration
The USPTO has granted Washington University a patent (US12582649B2) for compositions and methods for hair follicle regeneration using TRPV4 activating agents. The patent aims to treat hair loss conditions such as alopecia and telogen effluvium.
USPTO Patent Grant: Dopamine D3 Agonists for CNS Disorders
The USPTO has granted patent US12582648B2 to Bioprojet Pharma for a method of treating central nervous system disorders, including restless leg syndrome and neurodegenerative diseases, using dopamine D3 partial agonists. The patent details specific applications and classifications related to these therapeutic uses.
USPTO Patent US12582642B2 for Treating Bovine Papillomatosis
The USPTO has granted patent US12582642B2 to KINOPHARMA, INC. for a composition and method to treat bovine papillomatosis. The patent covers compounds represented by Formula (I) or their pharmaceutically acceptable salts.
USPTO Grants Patent for Sulfur Compound in Tumor Treatment
The USPTO has granted patent US12582641B2 to SHANGHAITECH UNIVERSITY for a sulfur-containing compound based on a glutarimide skeleton and its application in treating tumors. The patent filing date was February 25, 2020, and the grant date is March 24, 2026.
USPTO Patent Granted for Cancer Treatment with ERK Inhibitors
The USPTO has granted a patent (US12582635B2) to Biomed Valley Discoveries, Inc. for methods of treating cancer with atypical BRAF mutations using ERK inhibitors. The patent covers compositions, methods for treatment, and identification of suitable patient populations.
Donepezil Topical Formulation Patent for Intradermal Use
The USPTO has granted a patent (US12582637B2) to Arctic Therapeutics HF for a topical formulation of donepezil intended for intradermal application. The patent covers compositions and methods of use for this specific formulation.
A2A Receptor Antagonist Salt and Crystal Forms
The USPTO has granted patent US12583869B2 for a salt form and crystal form of an adenosine A2A receptor antagonist, along with its preparation method. The patent, assigned to CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD., also covers the application of these forms in preparing medicine for A2A receptor-related diseases.
USPTO Patent Grant US12583859B2 for PRMT5 Inhibitors
The USPTO has granted patent US12583859B2 to the California Institute of Technology for PRMT5 inhibitors. The patent covers compounds and methods useful in treating cancers and other diseases.
USPTO Patent Grant: PSMA Imaging Agents
The United States Patent and Trademark Office (USPTO) has granted patent US12583887B2 to Siemens Medical Solutions USA, Inc. for PSMA imaging agents. The patent covers compounds and methods for imaging prostate-specific membrane antigen (PSMA), suitable for PET and SPECT imaging.
USPTO Patent Grant: Pyridone Derivative Crystal Form
The USPTO has granted a patent to Jiangxi Caishi Pharmaceutical Technology Co., Ltd. for a novel pyridone derivative crystal form and its preparation method. This patent covers specific crystal forms and their application in treating influenza, potentially offering improved efficacy and bioavailability.
USPTO Patent Grant: Light-Emitting Element with Long Lifetime
The USPTO has granted a patent (US12588408B2) to Semiconductor Energy Laboratory Co., Ltd. for a novel light-emitting element. The patent describes an element with a long lifetime and high efficiency, utilizing specific organic acceptor and host materials in its electron-transport layers.
USPTO Patent Grant: Daprodustat Crystal Form M Preparation and Use
The USPTO has granted patent US12583823B2 for a specific crystal form (crystal form M) of the drug daprodustat, a proline hydroxylase inhibitor. The patent covers the preparation method and use of this crystal form, which exhibits improved stability and solubility characteristics.
USPTO Patent Grant: Chemokine CXCR4 Receptor Modulators
The USPTO has granted a patent to Emory University for chemokine CXCR4 receptor modulators and their uses. The patent covers compounds and pharmaceutical compositions that can be used for managing various conditions including viral infections, abnormal cellular proliferation, and cancer.
USPTO Patent Grant US12582652B2 for Ion Channel Modulator
The USPTO has granted patent US12582652B2 to Praxis Precision Medicines, Inc. for a novel ion channel modulator compound. The patent covers methods of treating neurological disorders and conditions associated with neuronal excitability.
Biomaterial with functionalized tyrosine, preparation method, pharmaceutical composition
The USPTO has granted a patent (US12583818B2) for a method to prepare a biomaterial with selectively functionalized tyrosine and a pharmaceutical composition containing it. This innovation aims to improve the efficacy of biomaterial drugs by ensuring selective coupling to tyrosine without affecting other amino acids or the biomaterial's inherent activity.
USPTO Patent US12583820B2: Antivirals against coronavirus
The USPTO has granted patent US12583820B2 to Kansas State University Research Foundation for broad spectrum antivirals against coronaviruses. The patent covers specific chemical compounds designed to inhibit viral replication.
Omecamtiv Mecarbil Salt and Preparation Process
The USPTO has granted US Patent 12583821B2 to Cytokinetics, Inc. for a specific salt form of omecamtiv mecarbil and its preparation process. This patent covers the dihydrochloride salt form, related compositions, and methods of use, primarily impacting pharmaceutical development and intellectual property.
USPTO Patent Grant: Benzylamine Derivative for Anti-Tumor Efficacy
The USPTO has granted a patent (US12583822B2) to the Academy of Military Medical Sciences for a benzylamine derivative with potential anti-tumor efficacy. The patent covers the derivative, its preparation method, and its use in treating PD-1/PD-L1-related diseases.
Redona Therapeutics Cancer Treatment Compounds Patent Grant
The USPTO has granted Redona Therapeutics, Inc. a patent (US12583825B2) for novel cancer treatment compounds. The patent covers specific benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives and their use in treating neoplastic diseases.
USPTO Patent for Acetic Acid Derivatives as Safeners
The USPTO has granted a patent (US12583826B2) to Bayer Aktiengesellschaft for acetic acid derivatives and salts thereof, intended for use as safeners in crop protection compositions. These compounds aim to reduce the phytotoxic effects of agrochemicals, particularly herbicides.
USPTO Patent Grant: Process for Ethyleneamines and Ethanolamines Manufacture
The USPTO has granted patent US12583827B2 to BASF SE for a new process to manufacture ethyleneamines and ethanolamines. The patent details a two-step process involving the conversion of glycolaldehyde derivatives and an aminating agent, followed by hydrogenation.
USPTO Patent US12583828B2: Aromatic Carbonyl Compounds Preparation Process
The USPTO has granted patent US12583828B2 to BASF SE for a process to prepare aromatic carbonyl compounds. The patent describes a catalytic oxidation method using molecular oxygen, a cobalt(II) salt, and N,N′,N″-trihydroxyisocyanuric acid (THICA).
USPTO Patent Grant: Oxetane Derivative Synthesis Method by Microreactor
The USPTO has granted a patent (US12583830B2) for a microreactor-based synthesis method for oxetane derivatives. The patent, assigned to Changzhou Tronly Advanced Electronic Materials Co., Ltd., details a process that improves efficiency, yield, and safety compared to traditional methods.
USPTO Patent Grant US12583831B2 for Hydrogenation Processes
The USPTO has granted patent US12583831B2 to Archer-Daniels-Midland Company for selective hydrogenation processes and catalysts. The patent covers methods for upgrading impure feedstocks, such as those derived from biomass, to increase the concentration of valuable intermediates like glycolaldehyde and hydroxyacetone.
USPTO Patent Grant: Diastereomer-Enriched Odorant Mixture Preparation
The USPTO has granted patent US12583833B2 to Symrise AG for a distillative process to prepare a diastereomer-enriched odorant mixture. The patent covers the process, the enriched mixture, and its use in perfumery to impart or enhance floral odor notes.
USPTO Patent Grant: Bacterial Infection Treatment Compound
The USPTO has granted a patent (US12583834B2) for a compound and pharmaceutical composition designed to treat bacterial infections by inhibiting Mfd activity. The patent was filed on February 19, 2021, and is assigned to INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT.
USPTO Patent Grant: PD-L1 Antagonist Compound
The USPTO has granted a patent (US12583839B2) to ADLAI NORTYE BIOPHARMA CO., LTD. for a PD-L1 antagonist compound and its pharmaceutical composition. The patent covers compounds of Formula (I) and their use in treating immune-related disorders.
USPTO Patent US12583840B2 for Androgen Receptor Antagonists Preparation
The USPTO has granted patent US12583840B2 to Orion Corporation for a method of preparing androgen receptor antagonists and their intermediates. The patent details a process using a heterogeneous palladium catalyst for the preparation of a specific benzonitrile compound useful in the synthesis of carboxamide-structured androgen receptor antagonists.
USPTO Patent Grant for Insomnia and Depression Compound
The USPTO has granted a patent (US12583841B2) to Breakthrough Pharmaceuticals Inc. for a tetrahydropyrrolocyclic compound and its application in preparing drugs to treat insomnia and depression by targeting the selective orexin-2 receptor. The patent was filed on January 27, 2022, and granted on March 24, 2026.
USPTO Patent Grant: Crystal Form of Nitroxoline Prodrug
The USPTO has granted patent US12583835B2 for a crystal form of a nitroxoline prodrug, a pharmaceutical composition containing it, and its preparation and application. The patent, assigned to Jiangsu Yahong Meditech Co., Ltd., describes crystal forms A and B with improved properties for industrial production and drug efficacy compared to nitroxoline.
USPTO Patent US12583838B2 for Kinase Inhibitors
The USPTO has granted patent US12583838B2 to Insilico Medicine Hong Kong Limited for kinase inhibitors designed for disease treatment. The patent covers specific compounds and their use in pharmaceutical compositions and methods for treating diseases.
USPTO Patent Grant US12583844B2: Hydantoin MMP Inhibitors
The USPTO has granted patent US12583844B2 to Foresee Pharmaceuticals USA, Inc. for hydantoin-based compounds that act as inhibitors of matrix metalloproteinases (MMPs), particularly MMP-12. The patent covers compositions and methods for treating various diseases mediated by MMP-12.
USPTO Patent Grant for Trinucleotide Repeat Disease Treatment
The USPTO has granted a patent (US12583845B2) to The Research Foundation for The State University of New York for compositions and methods to treat diseases involving trinucleotide repeats. The patent covers novel compounds and synthesis processes aimed at inhibiting microsatellite promoted expression of deleterious expansions.
USPTO Patent Grant: Benzopyran Derivatives as CRAC Inhibitors
The USPTO has granted a patent (US12583846B2) for benzopyran derivatives identified as CRAC inhibitors. The patent, filed on September 25, 2020, covers compounds represented by a specific formula, isomers, or pharmaceutically acceptable salts thereof, and their application in preparing CRAC inhibitors.
USPTO Patent Grant for Fluorinated Pyrimidine Compound Production
The USPTO has granted a patent (US12583847B2) to UNIMATEC CO., LTD. for a fluorinated pyrimidine compound and its production method. The patent covers specific chemical structures and synthesis processes, with a filing date of March 16, 2022.
USPTO Patent US12583848B2: Isoxazole Derivatives for Viral Infections
The USPTO has granted patent US12583848B2 to Universitätsklinikum Jena for isoxazole-3-carboxamide derivatives used in treating viral infections. The patent describes compounds effective against various viruses, including resistant strains, with low induction of cytochrome P4503A4.
USPTO Patent US12583849B2 for KCNT1 Inhibitors
The USPTO has granted patent US12583849B2 to PRAXIS PRECISION MEDICINES, INC. for KCNT1 inhibitors and methods of use. This patent covers compounds and compositions for treating neurological diseases, conditions related to excessive neuronal excitability, and gain-of-function mutations in genes like KCNT1.
USPTO Patent Grant: Pyrazine Derivatives for Pest Control
The USPTO has granted patent US12583851B2 to Elanco Animal Health GmbH for novel heteroaryl-substituted pyrazine derivatives. These compounds are intended for controlling animal pests, arthropods, insects in plant protection, and ectoparasites on animals.
USPTO Patent Grant: Heterocycle Derivative for Hair Loss Therapy
The USPTO has granted patent US12583852B2 for a novel heterocycle derivative, assigned to JW PHARMACEUTICAL CORPORATION. This patent covers compounds effective for the therapy and prevention of hair loss, including androgenic alopecia and alopecia areata.
USPTO Patent Grant for BCL-2 Inhibitors
The USPTO has granted a patent (US12583853B2) to Newave Pharmaceutical Inc. for 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors. These compounds are intended for the treatment of neoplastic and autoimmune diseases.
Amgen KRAS G12C Inhibitors Patent Granted
The USPTO has granted Amgen Inc. a patent (US12583854B2) for KRAS G12C inhibitors and methods of using them to treat cancers. The patent covers compositions and methods for treating pancreatic, colorectal, and lung cancers.
USPTO Patent US12583857B2 for Anti-liferative Agents
The USPTO has granted patent US12583857B2 for anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines. The patent was granted to PHEON THERAPEUTICS LTD and covers compounds useful as medicaments, particularly as anti-proliferative agents.
Genentech, Inc. Granted Patent for TDO2 Inhibitors
The USPTO has granted Genentech, Inc. patent US12583858B2 for TDO2 inhibitors. These inhibitors are useful for modulating tryptophan 2,3 dioxygenase activity, treating immunosuppression, and enhancing anti-cancer treatments. The patent was filed on October 12, 2020.
USPTO Patent Grant for API Crystalline Form Preparation
The USPTO has granted patent US12583860B2 to Apotex Inc. for processes to prepare multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour. The patent covers methods involving mixing a solid API with a liquid or solid pharmaceutically acceptable entity in the presence of solvent vapour, utilizing standard rotary apparatus.
USPTO Grants Patent for Nanoporous Material for Ion Channels
The USPTO has granted a new patent (US12583863B2) to the University of Wyoming for a synthetically modifiable ion channel material. This material, a nanoporous structure with controlled electronic and ion transport properties, mimics natural zeolites and MOFs.
Organic EL Device with Different Host Materials
The USPTO has granted a patent for an organic electroluminescent (EL) device. The patent describes a device with two emitting layers, each containing a different host material and a compound that emits fluorescence with a main peak wavelength of 500 nm or less. The patent specifies a condition for the triplet energy of the host materials.
Biologically Active Taxane Analogs and Oral Treatment Methods - Patent Granted
The USPTO has granted a patent (US12583865B2) to Tapestry Pharmaceuticals, Inc. for biologically active taxane analogs and methods of oral treatment for cancer. The patent covers novel chemical compounds, compositions, manufacturing methods, and combinations with other therapeutic agents.
USPTO Patent Grant: IAP Antagonists for Cancer Treatment
The USPTO has granted a patent (US12583866B2) to BeOne Medicines I GmbH for novel pyrido[2,3-b][1,4]oxazine or tetrahydropyrido[2,3-b][1,4]oxazepine derivatives. These compounds act as antagonists of Inhibitors of Apoptosis Proteins (IAPs) and are intended for use in treating cancer by inducing or sensitizing cells to apoptotic cell death.
USPTO Patent Grant for PCSK9 Inhibitors
The USPTO has granted a patent (US12584120B2) to AstraZeneca AB for novel PCSK9 inhibitors and methods of use. The patent covers specific heteroaryl compounds that bind the PCSK9 protein, aiming to advance treatments for conditions related to cholesterol regulation.
USPTO Patent Grant: JAK Inhibitors Synthesis Methods
The USPTO has granted patent US12583868B2 for novel JAK inhibitors and methods for their synthesis and use, assigned to Galderma Holding SA. The patent covers compounds with formula (I) and their application in treating various diseases.
Azaheteroaryl Compound Patent Granted
The USPTO has granted patent US12583870B2 to SHANGHAI BLUERAY BIOPHARMA CO., LTD. for an azaheteroaryl compound and its preparation method. This patent covers compounds and compositions for treating diseases related to EED protein and PRC2 protein complex mechanisms.
USPTO Grants PRMT5 Inhibitors Patent to Merck Sharp & Dohme
The USPTO has granted a new patent (US12583871B2) to Merck Sharp & Dohme LLC for PRMT5 inhibitors. The patent covers compounds and methods for treating conditions such as cancer, sickle cell, and hereditary persistence of foetal hemoglobin.
HSA Seized Over 1 Million Illegal Health Products in 2025
Singapore's Health Sciences Authority (HSA) reported seizing over 1 million illegal health products in 2025, a 10% increase from the previous year. The agency also removed 2,358 online listings, a significant decrease from previous years due to increased surveillance and collaboration with platforms. The enforcement actions targeted cough syrups, sexual enhancement medicines, and sedatives.
WHO Recommends New Diagnostic Tools for Tuberculosis
The World Health Organization (WHO) has issued new guidelines recommending innovative diagnostic tools for tuberculosis (TB), including near-point-of-care tests and tongue swabs. These recommendations aim to accelerate diagnosis, reduce costs, and expand access to lifesaving services, particularly in resource-constrained settings.
FDA Extends Coral Snake Antivenin Expiration Date
The FDA has extended the expiration date for Lot CL6814 of Antivenin (Micrurus fulvius) (Equine Origin), commonly known as North American Coral Snake Antivenin, from June 30, 2025, to June 30, 2026. This extension is based on stability data indicating the lot will maintain potency for an additional year.
ANSM Safety Information: Urology/Gynecology Suction Device
The French ANSM has been informed of a lot recall initiated by Clinical Innovations, LLC for their KIWI Omni Vacuum Delivery System suction device. This safety action is registered under number R2607844 and is directed at pharmacies and healthcare facilities.
ANSM Safety Alert: Manual Ventilator
The French ANSM has updated a safety alert regarding manual ventilators (Bavu) manufactured by Intersurgical. This update expands the scope of devices affected by a previous safety action initiated in May 2025, with users receiving updated correspondence.
ANSM Safety Alert: Kwik-Stik and Lyfo Disk Campylobacter jejuni Controls
The French National Agency for Medicines and Health Products Safety (ANSM) has issued a safety alert regarding bacteriology controls for Kwik-Stik and Lyfo Disk Campylobacter jejuni products from Microbiologics. This notice informs laboratories of a security action implemented by the manufacturer.
MHRA Phases Out Animal Testing with Early Data Review
The MHRA is phasing out animal testing by offering early reviews of non-animal data for drug marketing applications. This initiative aims to boost developer confidence in New Approach Methodologies (NAMs) and support the government's strategy to reduce animal use in research, while maintaining rigorous safety and efficacy standards.
MHRA Field Safety Notices for Medical Devices (March 16-20, 2026)
The MHRA has published a list of seven Field Safety Notices (FSNs) related to medical devices issued between March 16 and March 20, 2026. These notices are published for informational purposes, and recipients are advised to act on any FSN received from a manufacturer.
Hibiwash Recalled Due to Microbial Contamination
The MHRA has issued a precautionary recall for three batches of Hibiwash, an antimicrobial wash, due to microbial contamination identified at the manufacturing facility. Mölnlycke Health Care is advising healthcare professionals and retailers to stop supplying the affected batches and patients to stop using them.
DEA Memphis Arrests and Seizures
The DEA announced significant arrests and seizures in Memphis, Tennessee, including fentanyl, cocaine, meth, and numerous firearms. Administrator Cole provided remarks on the operation's success in combating drug trafficking and enhancing public safety.
DEA Phoenix Seizes 3 Million Fentanyl Pills in Arizona
The DEA Phoenix Division announced the seizure of nearly three million fentanyl pills in Arizona as part of Phase II of Operation FentanylFreeAmerica. This significant bust highlights ongoing efforts to combat the flow of illicit synthetic opioids.
DEA Omaha Seizes 70 Pounds of Methamphetamine
The DEA's Omaha Division announced the seizure of 70 pounds of methamphetamine. This action highlights ongoing efforts by law enforcement agencies to combat illicit drug trafficking.
USPTO Patent Grant for Cancer Diagnosis using Anti-BAG2 Antibody
The USPTO has granted a patent (US12583915B2) to Medpacto, Inc. for methods of diagnosing cancer using an anti-BAG2 antibody. The patent covers compositions comprising antibodies that specifically bind to BAG2 polypeptides or fragments thereof.
USPTO Patent Grant for LRP6 Protein Binding Antibodies
The USPTO has granted a patent (US12583919B2) to Antlera Therapeutics Inc. for antibodies that specifically bind to LRP6 proteins and methods of their use. The patent was filed on August 14, 2020, and is set to be granted on March 24, 2026.
USPTO Patent Grant for Caged-Degron Molecular Feedback Circuits
The USPTO has granted patent US12583896B2 to The Regents of the University of California for caged-degron-based molecular feedback circuits. The patent covers methods of modulating signaling pathways in cells using these circuits, with a filing date of January 6, 2020.
USPTO Patent Grant: DNA-binding domain transactivators
The USPTO has granted a patent (US12583902B2) to the University of Massachusetts for DNA-binding domain transactivators and their uses. The patent covers recombinant adeno-associated viruses (rAAVs) designed to modify target gene expression in cells.
USPTO Patent Grant: Modified Plasma Clotting Factor VIII
The USPTO has granted patent US12583907B2 to AAVnerGene, INC. for modified human factor VIII polypeptides with enhanced activity. These polypeptides and their encoding viral vectors are intended for treating FVIII deficiencies, such as hemophilia A.
USPTO Patent US12583917B2: IL17A Antibodies for Veterinary Use
The USPTO has granted patent US12583917B2 to Elanco US Inc. for IL17A antibodies and antagonists intended for treating conditions in animals, including companion animals. The patent details specific antibody embodiments and IgG Fc variant polypeptides designed to reduce immune responses.
Mutant Myocilin Disease Model Patent Granted
The USPTO has granted Regeneron Pharmaceuticals, Inc. a patent (US12582104B2) for a mutant myocilin disease model. This patent covers non-human animal models engineered to express human myocilin, intended for assessing therapeutic reagents for glaucoma.
Amgen Inc. Patent for KRAS G12C Inhibitor Cancer Therapy
The USPTO has granted Amgen Inc. a patent (US12582657B2) for a combination therapy involving a KRAS G12C inhibitor and other agents for treating cancers. The patent covers pharmaceutical compositions and methods of treatment.
USPTO Patent Grant: RAS Oncoprotein Inhibitors
The USPTO has granted patent US12582660B2 to the University of Louisville Research Foundation, Inc. for inhibitors of the RAS oncoprotein, methods of making, and methods of use thereof. The patent covers compounds useful in treating diseases associated with activating mutations in RAS, particularly cancer.
USPTO Patent Granted for Anti-Pro/Latent Myostatin Antibodies
The USPTO has granted a patent (US12582712B2) to Scholar Rock, Inc. for a method of making anti-pro/latent myostatin antibodies. The patent covers antibodies that specifically bind proMyostatin and/or latent Myostatin and their uses.
USPTO Grants Patent for Anti-CD73 Antibody and Use
The United States Patent and Trademark Office (USPTO) has granted patent US12583933B2 to BIOTHEUS INC. for an anti-CD73 antibody and its use in enhancing immune response and treating tumors. The patent was filed on August 28, 2020, and is effective March 24, 2026.
USPTO Patent Grant for Tumor Diagnosis and Treatment
The USPTO has granted patent US12583937B2 to Genentech, Inc. for compositions and methods related to the diagnosis and treatment of tumors in mammals. The patent, filed on March 16, 2022, includes 6 claims.
Bi-specific Peptides for Cancer Treatment Granted Patent
The USPTO has granted a patent (US12583888B2) to the University of Tartu for bi-specific peptides designed to target cancer cells and the extracellular matrix. These peptides bind to fibronectin extra domain B (FN-EDB) and/or tenascin-C C domain (TNC-C). The patent was granted on March 24, 2026.
USPTO Patent Grant for Peptides Treating Type 1 Diabetes
The USPTO has granted patent US12583891B2 to PHOENIX ALPHA for peptides and methods used in the treatment of type 1 diabetes. The patent covers specific peptide sequences and their application in generating cytolytic CD4+ T cells.
USPTO Patent Grant US12583892B2: Conus Peptides for Neurodegenerative Conditions
The USPTO has granted patent US12583892B2 to Technion Research and Development Foundation Limited for modified Conantokin peptides and their use in treating neurodegenerative conditions. The patent covers specific peptide forms, nucleic acids encoding them, and compositions for modulating NMDA receptors.
USPTO Patent Grant for T Cell Antigen Receptor Complex
The USPTO has granted patent US12583910B2 to Tsinghua University for a T cell antigen receptor complex and its preparation method. This patent covers antibodies, T cell receptors, and immune cells designed to recognize pMHC complexes and activate T cells for therapeutic use.
USPTO Patent Grant: Antibody Inhibitors for Staphylococcus Aureus Treatment
The USPTO has granted patent US12583913B2 for antibody inhibitors targeting Staphylococcus aureus, specifically coagulases SC and vWbp. This patent covers therapeutic methods and detection techniques utilizing these monoclonal antibodies.
USPTO Patent Granted for Dissociative Disorder Treatment Methods
The USPTO has granted a patent (US12582616B2) to The Board of Trustees of the Leland Stanford Junior University for methods of treating dissociative disorders. The patent covers agents that modulate neural activity in the posteromedial cortex to treat these conditions.
Patent: ROS-detonable Nanoclusters for Anti-Restenotic Therapy
The USPTO has granted a patent (US12582613B2) for biomimetic, reactive oxygen species-detonable nanoclusters designed for anti-restenotic therapy. The technology, assigned to the University of Virginia Patent Foundation, involves nanoclusters with self-assembled cores and biomimetic membrane coatings that can deliver anti-restenotic drugs.
USPTO Grants Patent for Bis-biguanide Compounds in Cancer Management
The USPTO has granted a patent (US12582618B2) to Emory University for bis-biguanide compounds and pharmaceutical compositions for managing cancer, particularly lung cancer. The patent covers methods of treatment and related compositions, with an effective grant date of March 24, 2026.
Bifunctional compounds for degrading BTK via ubiquitin pathway
The USPTO has granted patent US12582722B2 to Nurix Therapeutics, Inc. for bifunctional compounds designed to degrade Bruton's tyrosine kinase (BTK) through the ubiquitin proteolytic pathway. The patent covers novel compounds and pharmaceutical compositions for treating various diseases.
USPTO Patent Grant: Theranostic Agents for PSMA Positive Cancers
The USPTO has granted a patent (US12582728B2) to Memorial Sloan Kettering Cancer Center for theranostic agents targeting PSMA positive cancers. The patent covers compositions and methods for detecting and treating cancer using novel radiohalogenated PSMA targeting agents for diagnostic imaging and radiation therapy.
USPTO Patent Grant: Kit for Producing and Storing Radiopharmaceuticals
The USPTO has granted patent US12582729B2 to Wake Forest University Health Sciences for a kit technology designed for the production and long-term storage of Zr-89-PET radiopharmaceuticals. The patent covers improved stability for radiopharmaceuticals and a method for their production.
Moderna Cancer Vaccines Patent Grant
The USPTO has granted patent US12582609B2 to ModernaTX, Inc. for cancer ribonucleic acid (RNA) vaccines. The patent covers cancer RNA vaccines, methods of use, and compositions. This grant is a routine notification of intellectual property protection.
USPTO Patent Grant: B-RAF Kinase Inhibitor Solid Dispersion
The USPTO has granted a patent to BeiGene, Ltd. for a stable solid dispersion of a B-RAF kinase dimer inhibitor, Compound 1. The patent covers the composition, methods of preparation, and uses of this solid dispersion, as well as a crystalline form of Compound 1.
USPTO Patent Grant: Topical Anti-inflammatory Composition with Zileuton
The USPTO has granted a patent (US12582598B2) to QURIENT CO., LTD. for a topical anti-inflammatory pharmaceutical composition comprising Zileuton. The patent covers the composition, its uses, and methods of preparation.
USPTO Grants Patent for ACE Inhibitor and Blood Pressure-Lowering Agent
The USPTO has granted a patent (US12582146B2) to MARUZEN PHARMACEUTICALS CO., LTD. for an angiotensin-converting enzyme inhibitor and blood pressure-lowering agent containing a specific compound. The patent also covers beverages and food products incorporating this compound.
HHS Adopts Standards for Health Care Claims Attachments and Electronic Signatures
The Department of Health and Human Services (HHS) has finalized standards for health care claims attachments transactions and electronic signatures. This rule aims to streamline administrative processes within the healthcare industry by adopting new standards for these transactions.
Andrew Merdinyan - Pharmacy Technician License Surrender
The New Hampshire Board of Pharmacy has accepted the voluntary surrender of Andrew Merdinyan's pharmacy technician license (PhT-131188) due to allegations of controlled drug diversion. Merdinyan allegedly diverted approximately 1,236 tablets/capsules from a Walgreens pharmacy.
NH Board of Pharmacy - Emergency Suspension of Pharmacist License
The New Hampshire Board of Pharmacy has issued an emergency order suspending the license of pharmacist Justin Eric Lachance. The suspension follows findings of suspected diversion of controlled substances, including Clonazepam and Zolpidem, observed via Walgreens surveillance and confessed by the licensee.
Walmart Pharmacy Disciplinary Final Order
The New Hampshire Board of Pharmacy issued a disciplinary final order against Walmart Pharmacy concerning multiple locations. The order details the procedures and timelines for filing petitions for rehearing and the right to appeal the decision to the New Hampshire Supreme Court.
Felicia Dern - Voluntary Surrender of Pharmacy Tech License
The New Hampshire Board of Pharmacy has accepted the voluntary surrender of Felicia Dern's Registered Pharmacy Technician license (PHT-130661). This action follows allegations of drug diversion and substance misuse disorder, which led to her termination from Rite Aid.
Andrew Merdinyan License Emergency Suspension Order
The New Hampshire Board of Pharmacy has issued an emergency suspension order for the license of Andrew Merdinyan, a Registered Pharmacy Technician. The suspension is due to findings of probable cause that the licensee engaged in conduct posing an imminent danger to public health, safety, and welfare, including admitting to taking controlled medications from a pharmacy.
GA Board of Pharmacy Actions - January 2025
The Georgia Board of Pharmacy has revoked the registration of Yental Breanna Alford (PHTC051190) in its January 2025 public actions list. This action pertains to a pharmacy technician.
Georgia Pharmacy Board Actions - January 2026
The Georgia Board of Pharmacy has issued its January 2026 Public Board Actions List. This list details enforcement actions taken against licensees, including the summary suspension of a facility's license and the lifting of a pharmacist's suspension. Specific licensee names and license numbers are provided for each action.
Georgia Board of Pharmacy Consent Orders and Revoked Registrations
The Georgia Board of Pharmacy has issued consent orders for Musely Compounding Pharmacy East LLC and Cornerstone Medical, Inc. Additionally, registrations for technicians Amira Jayde Brooks and Cythnia Elaine Brannon have been revoked.
GA Board of Pharmacy Actions - February 2025
The Georgia Board of Pharmacy has issued a list of actions taken in February 2025. These actions include a voluntary cease and desist order for Steri-Tek PHWH004241 and a consent order for S2 Medical Supply, LLC (PHDME000685). Specific details on the nature of violations or penalties are not provided in this summary.
Georgia Pharmacy Board Actions - February 2026
The Georgia Board of Pharmacy has issued a list of actions taken in February 2026. These actions include a voluntary surrender for a technician and a consent order for a facility, Xttrium Laboratories, Inc. Specific details on the nature of the consent order and surrender are pending further documentation.
National Institute on Deafness and Other Communication Disorders Notice of Closed Meetings
The National Institutes of Health (NIH) has issued a notice regarding upcoming closed meetings for the National Institute on Deafness and Other Communication Disorders. These meetings are scheduled for April 27, 2026. The notice provides details on the dates of these sessions.
NIH Loan Repayment Programs OMB Review Comment Request
The National Institutes of Health (NIH) has submitted a request for Office of Management and Budget (OMB) review regarding its Loan Repayment Programs. This notice is a 30-day comment request, allowing interested parties to provide feedback on the information collection associated with these programs.
NIH Strategic Plan Framework FY2027-2031 Request for Comments
The National Institutes of Health (NIH) is seeking public comments on a framework for its agency-wide strategic plan for Fiscal Years 2027-2031. This Request for Information (RFI) aims to gather input to shape the NIH's future research priorities and initiatives.
NIH Office of the Director Charter Renewal Notice
The National Institutes of Health (NIH) has published a notice in the Federal Register regarding the renewal of the charter for its Office of the Director. This notice serves to inform the public about the continuation of this advisory committee.
Center for Scientific Review Closed Meetings Notice
The National Institutes of Health (NIH) published a notice regarding upcoming closed meetings for the Center for Scientific Review. These meetings are part of the standard review process for grant applications and do not involve new regulatory requirements.
FDA Delays Effective Date for Beetroot Red Color Additive
The Food and Drug Administration (FDA) has delayed the effective date for the final order concerning the color additive Beetroot Red. The original effective date of February 6, 2026, is now indefinitely postponed, with the FDA to announce a new effective date or further administrative action via a future Federal Register notice.
Spirulina Extract Color Additive Effective Date Delayed
The FDA has delayed the effective date of its final order regarding spirulina extract as a color additive. The original effective date of February 6, 2026, is now indefinitely postponed, with a new effective date to be announced via a future Federal Register publication.
FDA Complaint Document
The FDA has posted a complaint document related to its Center for Tobacco Products (CTP). The document is available for review on Regulations.gov, though no specific details about the complaint's content are provided in the metadata.
FDA Complaint Received
The FDA received a complaint on March 23, 2026, related to tobacco products. The complaint document is available for review, though no specific details or actions are provided within the metadata.
FDA Complaint Document
The FDA has posted a complaint document related to its regulatory activities. The document is available for review via the provided URL, with an attachment labeled 'Complaint' authored by CTP.
FDA Complaint Posted
The FDA has posted a complaint related to tobacco products, authored by CTP. The document was made available on March 23, 2026, and the comment period has closed.
FDA Complaint Document
The FDA has posted a complaint document related to tobacco product regulations, authored by the Center for Tobacco Products (CTP). This document is open for public comment until March 23, 2026.
FDA Completeness Assessment Correspondence
The FDA has posted Completeness Assessment Correspondence related to drug applications. This notice provides information from the Center for Drug Evaluation and Research (CDER) regarding the completeness of submitted applications.
FDA Complaint Document Details
The Food and Drug Administration (FDA) has posted a complaint document related to its regulatory activities. The document is available for review, and the comment period for this specific item has closed.
FDA Complaint Filed and Closed for Comments
The FDA has filed a complaint related to pharmaceutical products, which has now been closed for public comment. The complaint was authored by CTP and is available for review on regulations.gov.
FDA Complaint Filed and Closed for Comments
The FDA has filed a complaint related to tobacco products, which is now open for public comment. The complaint was filed on March 23, 2026, and the comment period is ongoing.
FDA Complaint Filed
The FDA has filed a complaint on March 23, 2026, related to tobacco product regulation. The complaint was authored by the Center for Tobacco Products (CTP). Further details on the specific allegations and parties involved are expected to be available.
FDA Completeness Assessment Correspondence
The FDA has posted Completeness Assessment Correspondence related to drug applications. This notice indicates that specific correspondence documents are available for review, authored by CDER.
FDA Complaint Filed and Closed for Comments
The FDA has filed a complaint related to tobacco products, which is now open for public comment. The complaint was filed on March 23, 2026, and the comment period is active.
FDA CDER Final Response Letter to Rising Pharma Holdings
The FDA's Center for Drug Evaluation and Research (CDER) has issued a final response letter to Rising Pharma Holdings, Inc. The document details the agency's final decision regarding the company's submission. Specific details of the response are contained within the letter.
FDA Announces Public Hearing on CNPV Pilot Program
The FDA is announcing a public hearing on its Commissioner's National Priority Voucher (CNPV) Pilot Program, designed to expedite review times for qualifying new drug applications and biologics license applications. The agency is seeking feedback on program eligibility, selection processes, and review procedures.
FDA Complaint Document
The FDA has posted a complaint document related to its regulatory activities. The document is available for review on the Regulations.gov portal. No specific compliance actions or deadlines are indicated for regulated entities.
FDA CDER Final Response Letter to AdventaPharma DWC-LLC
The FDA's Center for Drug Evaluation and Research (CDER) has issued a final response letter to AdventaPharma DWC-LLC. This document is part of the ongoing regulatory process for drug applications and does not appear to contain new compliance obligations.
FDA Completeness Assessment Correspondence
The FDA has posted Completeness Assessment Correspondence related to drug applications. This notice indicates that documents are available for review concerning the completeness of certain regulatory submissions.
FDA CDER Response Letter to Laboflex, Inc.
The FDA's Center for Drug Evaluation and Research (CDER) has issued a response letter to Laboflex, Inc. The document is a final response, indicating a resolution or specific feedback on a matter concerning the company. No further details on the content or specific regulatory actions are available.
Animal Drug User Fees Reporting - Comment Period
The FDA is seeking public comment on proposed information collection provisions related to its animal drug and animal generic drug user fee programs. The comment period is open until May 22, 2026, as required by the Paperwork Reduction Act.
FDA Complaint Document Posted for Comments
The FDA has posted a complaint document related to tobacco products for public comment. The document is available for review and submission of feedback.
FDA Complaint Document
The FDA has posted a complaint document related to tobacco regulation, authored by CTP. This document is part of a public consultation process, with a comment period that has now closed.
FDA Complaint Document
The FDA has posted a complaint document related to its Center for Tobacco Products (CTP). The document was made available for public comment on March 23, 2026.
FDA Complaint Document
The FDA has posted a complaint document authored by CTP. The document is available for download via a link provided on the Regs.gov portal. No further details on the complaint's content or its regulatory implications are provided.
Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request
The Health Resources and Services Administration (HRSA) is requesting public comment on its plan to submit an information collection request to the Office of Management and Budget (OMB) for review and approval. This pertains to the Bureau of Health Workforce Performance Data Collection, OMB No. 0906-0086.
HRSA Rural Health Care Coordination Program Performance Measures
The Health Resources and Services Administration (HRSA) is proposing new performance measures for the Rural Health Care Coordination Program. This notice requests public comment on the proposed information collection activities, including the title of the collection and the associated OMB control number.
CDC: Nominations Sought for Mine Safety Research Advisory Committee
The Centers for Disease Control and Prevention (CDC) is seeking nominations for individuals to serve on the Mine Safety and Health Research Advisory Committee. The notice outlines the nomination process and the deadline for submissions.
CDC Proposed Data Collection for Public Comment
The Centers for Disease Control and Prevention (CDC) has submitted a proposed data collection for public comment. The comment period is open for 63 days, closing on May 26, 2026. This action allows the public to provide input on the proposed data collection initiative.
Proposed Data Collection for Public Comment
The Centers for Disease Control and Prevention (CDC) has submitted a proposed data collection for public comment. This notice provides instructions and deadlines for submitting feedback on the proposed data collection initiative.
CDC Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) has published a notice in the Federal Register regarding agency forms undergoing Paperwork Reduction Act (PRA) review. This notice informs the public about the forms that are subject to PRA review, which is a process to ensure federal agencies do not collect information from the public without appropriate justification and OMB approval.
USPTO Intent to Use Trademark Application for ZING
The USPTO has received an intent-to-use trademark application for the mark 'ZING' for use with medicated lozenges and non-medicated functional beverages. The application was filed on July 10, 2025, with an effective date of March 22, 2026.
USPTO Trademark Publication: Collagen Bio-Peptides Protein
The USPTO has published the trademark application for 'Collagen Bio-Peptides Protein' for nutritional supplements. The application was filed on August 5, 2025, and published for opposition on March 22, 2026.
Green Monkey Trademark Application Published
The USPTO has published the Green Monkey trademark application for herbal supplements for opposition. The application was filed on July 29, 2025, and published on March 22, 2026. This publication initiates a period during which third parties may oppose the trademark registration.
MACRO VITAL USPTO Trademark Application
The USPTO has received an intent-to-use trademark application for the mark 'MACRO VITAL'. The application covers a wide range of dietary and nutritional supplements, including drink mixes, enzyme supplements, protein shakes, and vitamin supplements. The filing date for this application was November 29, 2024.
USPTO Trademark Application: COMPRESSION ASSIST
The United States Patent and Trademark Office (USPTO) has received an intent-to-use trademark application for the mark 'COMPRESSION ASSIST'. The application covers personal lubricants and therapeutic sprays for muscle relaxation. The filing date was November 12, 2024.
USPTO Trademark Application for Pain Management
The USPTO has published a trademark application for "CUSTOM INTERVENTIONAL PAIN MANAGEMENT" for use with local anesthetics and customized medical kits. The application was published for opposition on March 22, 2026, with a filing date of September 24, 2024.
LHOPEBK NATURE Trademark Registration
The USPTO has registered the trademark LHOPEBK NATURE for a variety of dietary supplements, including alginate, casein, enzyme, glucose, lecithin, mineral, pollen, propolis, protein, royal jelly, whey protein, and yeast supplements. The registration was finalized on March 22, 2026, following a filing date of June 11, 2024.
LITIMIC Trademark Status Change
The USPTO has recorded a status change for the LITIMIC trademark application (TM99165165), which covers various pharmaceutical preparations. The status change is noted with an effective date of March 22, 2026.
Hyvia Health Intent to Use Trademark for Herbal Supplements
The USPTO has received an intent-to-use trademark application (TM99100449) from Hyvia Health for herbal supplements. The application covers products intended for longevity, memory, and mental health and clarity.
Centurion Health Trademark Published for Opposition
The United States Patent and Trademark Office (USPTO) has published the trademark application for 'Centurion Health' for opposition. The application covers a range of pharmaceutical products, including allergy medication, cough syrups, dietary supplements, and pain relief medication.
PAWGUS intent to use trademark application filed Mar 22, 2026
PAWGUS intent to use trademark application filed Mar 22, 2026
USPTO Trademark Publication: VIRIFLOW for Supplements
The USPTO has published the trademark application VIRIFLOW for dietary and nutritional supplements. The application was filed on November 19, 2025, and published for opposition on March 22, 2026. This publication marks a step in the trademark registration process.
USPTO Trademark Application for TARGETED SCIENCE
The United States Patent and Trademark Office (USPTO) has received an intent-to-use trademark application for the mark "TARGETED SCIENCE". The application covers various types of supplements, including vitamin, dietary, and nutritional supplements, particularly those for prostate health.
JETA Intent to Use Trademark for Beverages and Apparel
The USPTO has received an intent-to-use trademark application from JETA for various goods including empty bottles, drinkware, apparel, and nutritional supplements. The application covers products such as shaker bottles, scoops, frothers, activewear, headwear, socks, footwear, sports drinks, meal replacements, and various supplements.
VIOLA Trademark Published for Opposition
The USPTO has published the VIOLA trademark application for opposition. The application covers a range of pharmaceutical and medicinal products, including medicated ointments, skin care preparations, herbal supplements, and medicinal herbs. The publication date is March 22, 2026.
USPTO Trademark Application 99505416 Published for Opposition
The USPTO has published trademark application 99505416 for opposition. The application covers peptides, nucleotides, medicinals, and regenerative medicine. The publication date is March 22, 2026, with a filing date of November 19, 2025.
Intelligent Medicines Trademark Published for Opposition
The United States Patent and Trademark Office (USPTO) has published the trademark application for "INTELLIGENT MEDICINES" for opposition. The application covers goods and services related to peptides, nucleotides, medicinals, and regenerative medicine.
Anointed Inspired Remedies Trademark Application
The USPTO has received an intent-to-use trademark application for 'Anointed Inspired Remedies' by a pharmaceutical company. The application covers goods such as herbal teas, medicinal herbal preparations, and castor oil for medical purposes.
Micromacros Trademark Publication
The USPTO has published the trademark application for "Micromacros" for nutritional supplements. The application was filed on November 19, 2025, and published for opposition on March 22, 2026. This publication is a procedural step in the trademark registration process.
USPTO Trademark Application for CYTOFOOD
The USPTO has received an intent-to-use trademark application (TM99505302) for the mark "CYTOFOOD". The application covers a range of cosmetic products, including anti-aging cleansers, toners, lotions, moisturizers, serums, and facial masks, as well as various dietary and nutritional supplements.
Prostar Vitamins Trademark Publication
The USPTO has published the Prostar Vitamins trademark application for opposition. The application, filed on November 19, 2025, covers vitamin supplements and was published on March 22, 2026. This publication opens a period for third parties to oppose the trademark registration.
USPTO Trademark Application - Clinical Diagnostic Reagents
The USPTO has received an intent-to-use trademark application (TM99492783) for clinical diagnostic reagents and related medical imaging agents. The application was filed on November 12, 2025, with an effective date of March 22, 2026.
Yellowbird Intent to Use Trademark Application for Diagnostic Reagents
The USPTO has received an intent-to-use trademark application from Yellowbird for diagnostic reagents and radiopharmaceutical agents. The application covers a range of products used in medical imaging, cancer detection, and general diagnostics.
DALICAT Trademark Application Filed
The USPTO has received an intent-to-use trademark application for the mark 'DALICAT'. The application covers a range of pharmaceutical products and supplies for pets, including medicated shampoos, flea and tick treatments, dietary supplements, and dietetic foods for veterinary purposes. The filing date for this application was November 12, 2025.
PRODIAMAX Trademark Application Published for Opposition
The USPTO has published the trademark application for PRODIAMAX for opposition. The application covers a range of dietary, nutritional, and herbal supplements for weight management, energy, and general wellness. The filing date was November 12, 2025.
Green Pulse Intent to Use Trademark Application
The USPTO has received an Intent to Use trademark application for "Green Pulse" filed on November 12, 2025. The application covers a wide range of pharmaceutical and dietary supplement products, including multivitamins, bone and joint supplements, weight loss aids, and sleep aids.
USPTO Trademark Intent to Use Application Filed
The USPTO has received an intent to use trademark application for a wide range of supplements, including probiotic, homeopathic, mineral, herbal, vitamin, and protein-based products. The application was filed on November 12, 2025, for goods intended for use on March 22, 2026.
USPTO Trademark Application: TRIBLOCK 7
The USPTO has received an intent-to-use trademark application for the mark TRIBLOCK 7. The application covers dietary supplements, nutritional supplements, weight management supplements, and dietary and nutritional supplements for weight loss. The filing date was November 14, 2025.
USPTO Trademark Application: BE MAGIC, BE YOU
The USPTO has received an intent-to-use trademark application for the mark "BE MAGIC, BE YOU". The application covers dietary supplemental drinks, dietary supplements, and related educational and retail services. The filing date for this application was November 14, 2025.
USPTO Trademark Publication: Be Your Best Body
The USPTO has published the trademark application for 'Be Your Best Body' for opposition. The application covers unprocessed edible seeds and nutritional supplements, filed on November 14, 2025.
Creamatine Trademark Published for Opposition
The USPTO has published the trademark application for 'Creamatine' for opposition. The application, filed on November 12, 2025, covers dietary supplements and related products. The publication date is March 22, 2026.
CREAMATINE Trademark Published for Opposition
The United States Patent and Trademark Office (USPTO) has published the trademark application for 'CREAMATINE' for opposition. The application covers dietary supplements, dietary and nutritional supplements, and powdered nutritional supplement drink mix. The filing date was November 12, 2025.
FITTR Trademark Application Published for Opposition
The USPTO has published the FITTR trademark application for opposition. The application covers online retail services for dietary supplements and fitness products, as well as related business and marketing services. The filing date for this application was November 12, 2025.
USPTO Intent to Use Trademark Application: LUMOBO
The USPTO has received an intent-to-use trademark application for the mark LUMOBO, filed on November 12, 2025. The application pertains to dietary and nutritional supplements.
JYM Intent to Use Trademark Application for Energy Drinks
The USPTO has received an intent-to-use trademark application from JYM for various energy and sports drink products. The application was filed on November 12, 2025, and is designated for Class 005, which covers pharmaceuticals and veterinary preparations, but the listed goods are food and beverage items.
USPTO Intent to Use Trademark Application - JYM
The USPTO has received an Intent to Use trademark application (TM99492435) for the mark 'JYM'. The application covers powdered nutritional supplement drink mixes, protein supplements, and various sports drinks. The filing date for this application was November 12, 2025.
CHATEAL AX Trademark Application - Oral Contraceptives
The USPTO has received a trademark application for 'CHATEAL AX' for use in connection with oral contraceptives. The application was filed on November 12, 2025, under the 'intent to use' provision.
USPTO Trademark Application Published for Opposition: FOUR MAG
The USPTO has published the trademark application for "FOUR MAG" for opposition. The application, filed on November 12, 2025, covers food supplements and health food supplements. The publication date for opposition is March 22, 2026.
USPTO Trademark Application for AUBRA AX
The USPTO has received an intent-to-use trademark application for 'AUBRA AX', intended for use in connection with oral contraceptives. The application was filed on November 12, 2025.
RYOS Trademark Application Filed
The USPTO has received an intent-to-use trademark application for the mark RYOS, filed on November 12, 2025. The application covers goods classified as dietary supplements.
Lifestar Trademark Publication for Opposition
The USPTO has published the Lifestar trademark application for opposition. The application, filed on November 12, 2025, seeks to cover a full line of pharmaceutical and chemical preparations. The publication date is March 22, 2026.
INVIVOCAR Trademark Application - Intent to Use
The USPTO has received an Intent to Use trademark application for the mark 'INVIVOCAR'. The application covers pharmaceutical preparations for the treatment of cancer, autoimmune diseases, and infectious diseases. The filing date was November 12, 2025.
Omega 3 Basix Trademark Published for Opposition
The USPTO has published the trademark application for 'Omega 3 Basix' for opposition, with a publication date of March 22, 2026. The application covers dietary and nutritional supplements, including those containing enzymatically enhanced monoglyceride fish oils.
ADY Trademark Application Published for Opposition
The United States Patent and Trademark Office (USPTO) has published the trademark application for 'ADY' for opposition. The application covers a wide range of beverages, food supplements, and related products. The publication date for opposition is March 22, 2026.
THERAZURE Trademark Application Published for Opposition
The United States Patent and Trademark Office (USPTO) has published the trademark application for THERAZURE for opposition. The application covers veterinary preparations for treating thrush and other hoof ailments in equines and other hooved animals. The publication date is March 22, 2026.
USPTO Trademark Application for Hypawthesis
The USPTO has received an intent-to-use trademark application for the mark 'HYPAWTHESIS' for dietary supplements for dogs. The application was filed on November 12, 2025, with an intended effective date of March 22, 2026.
USPTO Trademark Application for Cosmetics and Supplements
The USPTO has received an intent-to-use trademark application (TM99492231) for various cosmetic and dietary supplement products. The application was filed on November 12, 2025, with an intended use date of March 22, 2026.
USPTO Trademark Application Published for Opposition
The USPTO has published trademark application TM99492217 for opposition. The application covers a wide range of cosmetic and beverage products, including skin moisturizers, creams, sports drinks, and dietary supplements. The filing date for this application was November 12, 2025.
USPTO Trademark Application Published for Opposition: TOP-Q
The USPTO has published the trademark application for 'TOP-Q' for opposition, covering various pharmaceutical and medical products. The application was filed on November 12, 2025, and the publication date for opposition is March 22, 2026.
MAEVA Intent to Use Trademark Application for Supplements
The USPTO has received an intent-to-use trademark application (TM99492340) for the mark 'MAEVA'. The application covers powdered supplement drink mixes, protein powders, and other nutritional powders for human consumption. The filing date for this application was November 12, 2025.
USPTO Trademark Application - Metabolic Hydration
The USPTO has received an intent-to-use trademark application for 'METABOLIC HYDRATION' for a powdered nutritional supplement drink mix. The application was filed on November 12, 2025, with an intended use date of March 22, 2026.
Navy St. Trademark Application - Intent to Use
The USPTO has received an intent-to-use trademark application for the mark 'NAVY ST.' filed on November 11, 2025. The application covers a range of pharmaceutical and cosmetic products, including acne treatments, medicated cosmetics, sunscreens, moisturizers, and hair care products.
USPTO Trademark Application for Honest Dose Supplements
The USPTO has received an intent-to-use trademark application for 'Honest Dose' for various supplements, including probiotic, vitamin, mineral, and herbal supplements. The application was filed on November 4, 2025, with an intended use date of March 22, 2026.
USPTO Trademark Publication: THE DAILY 4
The USPTO has published the trademark application for 'THE DAILY 4' for opposition. The application covers dietary and nutritional supplements, vitamin and mineral supplements, and online ordering services for these products. The filing date was November 4, 2025.
NUMIATE Trademark Intent to Use Application
The USPTO has received an intent to use trademark application for "NUMIATE" (TM99477578) filed on November 4, 2025. The application covers medicated and non-medicated skin care preparations. This filing indicates a future intention to use the mark in commerce.
USPTO Trademark Application - Equine Products Ireland
The USPTO has received an intent-to-use trademark application from Equine Products Ireland for vitamins and dietary food supplements for animals. The application was filed on October 30, 2025.
YOYOFOX Trademark Application Published for Opposition
The USPTO has published the YOYOFOX trademark application for opposition, covering self-adhesive dressings, elastic bandages, and hydrogel for medical purposes. The application was filed on October 21, 2025, and published on March 22, 2026.
PINAINICE Trademark Publication
The USPTO has published the trademark application for PINAINICE, covering various medicated skin care preparations and pharmaceutical substances. The application was filed on October 29, 2025, and published for opposition on March 22, 2026.
USPTO Trademark Application for Probelle
The USPTO has received an intent-to-use trademark application for the mark "Probelle" filed on October 28, 2025. The application covers goods including dietary supplements, nutritional supplements, and herbal supplements.
New You Pretty Energy Trademark Application
The United States Patent and Trademark Office (USPTO) has received a new trademark application for 'NEW YOU PRETTY ENERGY' filed on October 8, 2025. The application is for intent to use and covers various energy drinks, dietary supplements, and related products.
New You Pretty Sparkling Trademark Application Filed
The USPTO has received a new trademark application for 'New You Pretty Sparkling' filed by an unspecified entity. The application covers non-alcoholic carbonated beverages, carbonated waters, fruit-flavored beverages, sparkling water, and various dietary and nutritional supplements.
GOMAVU Trademark Application Published for Opposition
The USPTO has published the GOMAVU trademark application for opposition. The application, filed on September 16, 2025, covers products such as toilet deodorants and deodorizers. The publication date for opposition is March 22, 2026.
USPTO Intent to Use Trademark Application for Protein Bars
The USPTO has received an intent-to-use trademark application for 'Adam's Bar', intended for protein supplements formed and packaged as bars. The application was filed on August 29, 2025, with an expected use date of March 22, 2026.
Phazebreak Trademark Application for Protective Coatings
The USPTO has received an intent-to-use trademark application for the mark 'PHAZEBREAK'. The application covers a wide range of protective coatings and related services for industries including aerospace, wind turbines, and solar panels. This filing indicates a potential new market entrant or product line in specialized coating technologies.
METHL Trademark Registration - Vitamins
The USPTO has registered the trademark METHL for vitamins, filed on July 9, 2025, and officially registered on March 22, 2026. This registration pertains to intellectual property rights for a product within Class 005.
ECTODOL Trademark Renewal
The United States Patent and Trademark Office (USPTO) has renewed the trademark 'ECTODOL' (TM99273970) for pharmaceutical products. The renewal is effective until March 22, 2026.
MINICOO Trademark Application for Vitamin Supplements
The USPTO has received an intent-to-use trademark application for the mark "MINICOO" filed on July 4, 2025. The application covers a range of products including vitamin supplements, protein dietary supplements, and nutraceuticals for human and animal use.
USPTO Intent to Use Trademark Application - HY5
The USPTO has received an intent-to-use trademark application (TM99240025) for the mark 'HY5'. The application, filed on June 18, 2025, covers nutritional supplements and electrolyte replacement solutions.
ONEKEEP Trademark Registration
The USPTO has registered the trademark "ONEKEEP" for a range of pharmaceutical and health-related products, including nursing pads, herbal products, antimicrobial preparations, and dietary supplements. The registration was finalized on March 22, 2026, following a filing date of June 10, 2025.
OPTI + AREDS 2 Trademark Application
The USPTO has received an intent-to-use trademark application for 'OPTI + AREDS 2' filed on May 24, 2025. The application covers dietary and nutritional supplements for eye health.
USPTO Intent to Use Trademark Application: Velvet Hammer
The USPTO has received an intent to use trademark application for 'Velvet Hammer' filed on May 23, 2025. The application covers a powdered nutritional supplement drink mix and concentrate. This filing initiates the trademark registration process for the applicant.
Zerenne Trademark Registered for Dietary Supplements
The USPTO has registered the trademark ZERENNE (TM98895104) for use in connection with dietary supplements, natural sleep aid preparations, and nutritional supplements in gummy form. The trademark was registered on March 22, 2026, following a filing date of December 10, 2024.
USPTO Trademark Application: JUST DENTAL LAB
The USPTO has received an intent-to-use trademark application for 'JUST DENTAL LAB' filed on December 8, 2024. The application covers services related to custom dental prosthetics, dentures, and orthodontic retainers.
SUNIGHT Trademark Renewal
The USPTO has renewed the SUNIGHT trademark (TM99328696) for various pharmaceutical and health-related products. The renewal is effective March 22, 2026, and covers items such as sanitary towels, vitamins, health food supplements, and medicinal dressings.
SUNTROVE Trademark Renewal for Medical Supplies
The USPTO has renewed the SUNTROVE trademark (TM99324375) for a range of medical supplies and supplements. The renewal is effective March 22, 2026, and was filed on August 6, 2025. This action pertains to goods including bandages, disinfectants, vitamins, and dietary supplements.
USPTO Intent to Use Trademark Application for Runner Bar
The USPTO has received an intent-to-use trademark application for the mark 'Runner Bar' for various nutritional supplement bars. The application was filed on August 6, 2025, and is designated for use with products aimed at boosting energy and supporting endurance for athletes.
CYRED AX trademark application, intent to use, filed Nov 12, 2025
CYRED AX trademark application, intent to use, filed Nov 12, 2025
USPTO Intent to Use Trademark Application for LYLEQ AX
The USPTO has received an intent-to-use trademark application for the mark LYLEQ AX, filed on November 12, 2025. The application is for oral contraceptives. This filing indicates a future intention to use the mark in commerce.
USPTO Trademark Application for TRI-VYLIBRA AX
The USPTO has received an intent-to-use trademark application for the mark TRI-VYLIBRA AX, filed on November 12, 2025. The application is for oral contraceptives.
USPTO Trademark Application: TRI-VYLIBRA LO AX
The USPTO has received an intent-to-use trademark application for the mark TRI-VYLIBRA LO AX, filed on November 12, 2025. The application specifies its use in connection with oral contraceptives.
USPTO Trademark Application for VYLIBRA AX
The USPTO has received an intent-to-use trademark application for the mark VYLIBRA AX, filed on November 12, 2025. The application is for oral contraceptives. This filing indicates a future intent to use the mark in commerce.
USPTO Trademark Application for PR PDRN (POLYDEOXYRIBONUCLEOTIDE SODIUM) 10 G
The USPTO has received an intent-to-use trademark application for 'PR PDRN (POLYDEOXYRIBONUCLEOTIDE SODIUM) 10 G'. The application covers pharmaceutical preparations for skin care, including medicated creams and ointments for dermatological use and treating skin disorders.
Yellowbird Diagnostics Intent to Use Trademark Application
The USPTO has received an intent-to-use trademark application from Yellowbird Diagnostics for goods and services related to diagnostic reagents, contrast media, and radiopharmaceuticals. The application was filed on November 12, 2025, with an expected use date of March 22, 2026.
USPTO Trademark Application for ULIFE
The USPTO has received an intent-to-use trademark application for the mark 'ULIFE' filed on November 14, 2025. The application covers dietary supplements, vitamin and mineral supplements, protein supplements, meal replacement drink mixes, and nutraceuticals.
STAYSTRONG+ Trademark Application Filed
The USPTO has received an intent-to-use trademark application for STAYSTRONG+ filed on November 12, 2025. The application covers dietary supplements for humans. This filing indicates a future intention to use the mark in commerce.
Bybb Lifestyle Root Powders Trademark Published for Opposition
The USPTO has published the trademark application for 'Bybb Lifestyle Root Powders' for opposition. The application, filed on November 14, 2025, is for nutritional supplements and was published on March 22, 2026. This publication opens a period for third parties to oppose the trademark registration.
USPTO Trademark Application TM99497523 for pharmaceutical preparations
USPTO Trademark Application TM99497523 for pharmaceutical preparations
Fjor Supplements Trademark Published for Opposition
The USPTO has published the trademark application for 'Fjor Supplements' for opposition. The application covers health food and nutritional supplements for health and wellness. The filing date was November 19, 2025, and the publication date is March 22, 2026.
KREAFIX Trademark Application - Intent to Use
The USPTO has received an intent-to-use trademark application for the mark KREAFIX, filed on November 19, 2025. The application covers a range of dietary and nutritional supplements, primarily focused on creatine-based products.
USPTO Trademark Application for Morigella
The USPTO has received an intent-to-use trademark application for the mark "Morigella" by an unnamed applicant. The application covers various dietary supplements and related products. The filing date was November 16, 2025.
THG Teresa Health General Trademark Published for Opposition
The USPTO has published the trademark application for THG Teresa Health General for dietary supplements. The application was published for opposition on March 22, 2026, following a filing date of November 17, 2025. This publication initiates a period during which other parties may oppose the trademark's registration.
FORSYNTH Trademark Application - Intent to Use
The United States Patent and Trademark Office (USPTO) has received an intent-to-use trademark application (TM99497965) for the mark FORSYNTH. The application covers goods and services including dietary supplements, probiotic supplements, and related laboratory research services.
USPTO Trademark Application for IRONMEDS
The USPTO has received an intent-to-use trademark application for the mark IRONMEDS, filed on November 14, 2025. The application covers goods classified as dietary supplements, nutritional supplements, and vitamin supplements.
USPTO Trademark Application 99496083 - Herbal Supplements
The USPTO has received an intent-to-use trademark application (99496083) for herbal supplements. The application was filed on November 13, 2025, and is designated for use with herbal supplements.
USPTO Trademark Application ANIIREM - Intent to Use
The USPTO has published details for an intent-to-use trademark application (TM99505385) for the mark ANIIREM. The application covers various pharmaceutical and herbal products, including herbal tinctures, medicinal preparations, herbal supplements, castor oil for medical purposes, and tea-based beverages.
USPTO Trademark Application for Byheart Baby Food
The USPTO has received an intent-to-use trademark application for 'Byheart' baby food and infant formula. The application was filed on November 13, 2025, and includes the tagline 'THEY’RE NOT IN BREAST MILK, SO THEY’RE NOT IN BYHEART.'
USDA FSIS Public Health Alert for Ground Beef Products
The USDA's Food Safety and Inspection Service (FSIS) has issued a public health alert for ground beef products due to possible foreign material contamination. The alert covers products from a specific establishment and advises consumers on actions to take.